Furthermore, although extensive research has established the significant role played by the isocitrate dehydrogenase (IDH) mutation and the 1p/19q codeletion in the diagnosis, treatment, and prognostic assessment of glioma, the prognosis for afflicted patients remains unfavorable [1]. The gene discussed is IDH3A; the disease is central nervous system cancer.